ArticleClinical and experimental immunology2019
Clinical and laboratory features of seventy-eight UK patients with Good's syndrome (thymoma and hypogammaglobulinaemia).
Article in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- When the Good Syndrome Goes Bad: A Systematic Literature Review.Frontiers in immunology · 2021Pooled it
- Article
- Good's Syndrome Mirrors a Combined Immunodeficiency with Anti-Cytokine Antibodies in the Total Absence of B Cells.Journal of clinical immunology · 2026Article
- Significant decreased CXCR3Frontiers in immunology · 2026Article
- Mesenchymal stem cells-derived exosomes and Kaempferol improve myelin repair via attenuating inflammation and oxidative stress in a cuprizone-induced demyelination model.Stem cell research & therapy · 2025Article
- Aberrant Hematopoiesis and CD8Thoracic cancer · 2025Article
- Good's Syndrome Revealed by Recurrent Sigmoid Diverticulitis.European journal of case reports in internal medicine · 2025Article
- B cell deficiency in thymoma tissues of Good's syndrome patients.Discover oncology · 2024Article
- COVID-19 and Good's Syndrome After Thymectomy.Cureus · 2024Article
- Article
- COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.BMC cancer · 2024Article
- Thymoma with immunodeficiency, combined diffuse panbronchiolitis, and latent autoimmune diabetes in adults- case report and systematic review.Journal of translational autoimmunity · 2024Article
- Good's syndrome combined with CMV gastroenteritis: A case report and literature review.Clinical case reports · 2024Article
- Thymoma as a Potential Risk Factor for Nontuberculous Mycobacterial Pulmonary Disease: A Case Series.CHEST pulmonary · 2024Article
- Insights from a Case of Good's Syndrome (Immunodeficiency with Thymoma).Biomedicines · 2023Article
- In-depth blood immune profiling of Good syndrome patients.Frontiers in immunology · 2023Article
- Good's syndrome and COVID-19: case report and literature review.Mediastinum (Hong Kong, China) · 2023Article
- West Nile virus in a patient with Good's syndrome.Oxford medical case reports · 2022Article
- Relapsing cellulitis associated with Campylobacter coli bacteremia in a Good's syndrome patient: a case report.BMC infectious diseases · 2022Article
- First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction.Journal of clinical immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 14 institutions in 1 country.
Funding
Abstract
Good's syndrome (thymoma and hypogammaglobulinaemia) is a rare secondary immunodeficiency disease, previously reported in the published literature as mainly individual cases or small case series. We use the national UK-Primary Immune Deficiency (UKPID) registry to identify a large cohort of patients in the UK with this PID to review its clinical course, natural history and prognosis. Clinical information, laboratory data, treatment and outcome were collated and analysed. Seventy-eight patients with a median age of 64 years, 59% of whom were female, were reviewed. Median age of presentation was 54 years. Absolute B cell numbers and serum immunoglobulins were very low in all patients and all received immunoglobulin replacement therapy. All patients had undergone thymectomy and nine (12%) had thymic carcinoma (four locally invasive and five had disseminated disease) requiring adjuvant radiotherapy and/or chemotherapy. CD4 T cells were significantly lower in these patients with malignant thymoma. Seventy-four (95%) presented with infections, 35 (45%) had bronchiectasis, seven (9%) chronic sinusitis, but only eight (10%) had serious invasive fungal or viral infections. Patients with AB-type thymomas were more likely to have bronchiectasis. Twenty (26%) suffered from autoimmune diseases (pure red cell aplasia, hypothyroidism, arthritis, myasthenia gravis, systemic lupus erythematosus, Sjögren's syndrome). There was no association between thymoma type and autoimmunity. Seven (9%) patients had died. Good's syndrome is associated with significant morbidity relating to infectious and autoimmune complications. Prospective studies are required to understand why some patients with thymoma develop persistent hypogammaglobulinaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.